WebPhesgo is a combination medication containing pertuzumab, trastuzumab, and hyaluronidase or hyaluronidase-zzxf. It's a targeted anticancer treatment for HER2-positive breast cancer that’s either in the early or metastatic stage. Phesgo is an injection that’s given under the skin, and it’s typically used along with other chemotherapy. WebDiscontinue Phesgo in patients receiving adjuvant therapy and withhold in patients with metastatic disease for clinically significant decrease in LVEF; Embryofetal toxicity. Exposure to Phesgo can result in embryofetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal ...
FDA approves combination of pertuzumab, trastuzumab, and …
WebJun 29, 2024 · The recommended initial dose of PHESGO is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks... WebMar 25, 2024 · This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … polymer used in pharmaceutical drugs
PHESGO® (pertuzumab / trastuzumab / hyaluronidase …
WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … WebMar 2, 2024 · Phesgo contains two active substances, pertuzumab and trastuzumab, which are already authorised for treating early and metastatic HER2-positive breast cancer and … WebJan 12, 2024 · Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2024, the company's guidance fell short of Wall Street expectations. shanks location